Research graph
References from “A better system” – managing the adverse effects of prescribed medicines: Cluster-randomised controlled trial and process evaluation of the ADRe Profile in primary care. Local targets link to admitted publications; unresolved targets remain external evidence.
Incidence and preventability of adverse drug events in nursing homes
10.1016/s0002-9343(00)00451-4 · 2000 · External reference
Adverse drug events in ambulatory care
10.1056/nejmsa020703 · 2003 · External reference
Adverse events in British hospitals: preliminary retrospective record review
10.1136/bmj.322.7285.517 · 2001 · External reference
Unresolved reference
2015 · External reference
Trends in emergency hospital admissions in England due to adverse drug reactions: 2008-2015
10.1111/jphs.12160 · 2016 · External reference
Trends in adverse drug reaction-related hospitalisations over 13 years in New South Wales, Australia
10.1111/imj.14134 · 2019 · External reference
Ten-year trends in adverse drug reaction-related hospitalizations among people with dementia
10.1177/20420986221080796 · 2022 · External reference
Nobody ever questions-Polypharmacy in care homes: a mixed methods evaluation of a multidisciplinary medicines optimisation initiative
10.1371/journal.pone.0244519 · 2021 · External reference
Unresolved reference
2017 · External reference
Unresolved reference
2023 · External reference
Effect of underlying cardiometabolic diseases on the association between sedentary time and all-cause mortality in a large Japanese population: a cohort analysis based on the J-MICC study
10.1161/jaha.120.018293 · 2021 · External reference
Preventable adverse drug events: descriptive epidemiology
10.1111/bcp.14139 · 2020 · External reference
Costs associated with adverse drug reactions in an older population admitted to hospital: a prospective cohort study
10.1007/s00228-023-03552-x · 2023 · External reference
Incidence, nature and causes of avoidable significant harm in primary care in England: retrospective case note review
10.1136/bmjqs-2020-011405 · 2021 · External reference
Analysis of drug-related tinnitus based on the FDA adverse event reporting system database
10.12968/hmed.2024.0380 · 2024 · External reference
Drug-induced dementia: a real-world pharmacovigilance study using the FDA adverse event reporting system database
2025 · External reference
Prevalence of adverse drug reactions in the primary care setting: a systematic review and meta-analysis
10.1371/journal.pone.0252161 · 2021 · External reference
What is polypharmacy? A systematic review of definitions
10.1186/s12877-017-0621-2 · 2017 · External reference
Polypharmacy definitions for multimorbid older adults need stronger foundations to guide research, clinical practice and public health
2019 · External reference
Health outcomes and polypharmacy in elderly individuals: an integrated literature review
10.3928/0098-9134-20050901-04 · 2005 · External reference
Consequences of polypharmacy among the people living with dementia: a systematic review and meta-analysis
10.1080/13607863.2024.2436501 · 2025 · External reference
Unresolved reference
2012 · External reference
Is polypharmacy always hazardous? A retrospective cohort analysis using linked electronic health records from primary and secondary care
10.1111/bcp.12292 · 2014 · External reference
Prevalence of and risk factors for drug-related readmissions in older adults: a systematic review and meta-analysis
10.1007/s40266-023-01076-8 · 2024 · External reference
The effect of physical multimorbidity, mental health conditions and socioeconomic deprivation on unplanned admissions to hospital: a retrospective cohort study
10.1503/cmaj.121349 · 2013 · External reference
The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995-2010
10.1186/s12916-015-0322-7 · 2015 · External reference
An overview of prevalence, determinants and health outcomes of polypharmacy
10.1177/2042098620933741 · 2020 · External reference
Unresolved reference
2013 · External reference
Unresolved reference
External reference
Interventions to improve the appropriate use of polypharmacy for older people
2023 · External reference
Interventions to improve the appropriate use of polypharmacy in older people: a Cochrane systematic review
10.1136/bmjopen-2015-009235 · 2015 · External reference
Interventions to reduce adverse drug event-related outcomes in older adults: a systematic review and meta-analysis
10.1007/s40266-019-00738-w · 2020 · External reference
Detection tools for prediction and identification of adverse drug reactions in older patients: a systematic review and meta-analysis
10.1038/s41598-022-17410-w · 2022 · External reference
Interprofessional interventions involving pharmacists and targeting the medicines management process provided to older people residing in nursing homes: a systematic review and meta-analysis of randomised controlled trials
10.1007/s40266-022-00978-3 · 2022 · External reference
Evaluation of effectiveness and safety of pharmacist independent prescribers in care homes: cluster randomised controlled trial
10.1136/bmj-2022-071883 · 2023 · External reference
Correction to: guidelines for falls in older adults, medication reviews and deprescribing as a single intervention in falls prevention: a systematic review and meta-analysis, and, World guidelines for falls prevention and management for older adults: a global initiative
2023 · External reference
Interventions for reducing anticholinergic medication burden in older adults-a systematic review and meta-analysis
10.1093/ageing/afad176 · 2023 · External reference
The effect of deprescribing interventions on mortality and health outcomes in older people: an updated systematic review and meta-analysis
10.1111/bcp.16200 · 2024 · External reference
Emergency department programs to support medication safety in older adults: a systematic review and meta-analysis
10.1001/jamanetworkopen.2025.0814 · 2025 · External reference
Systematic review and meta-analysis of interventions to reduce adverse drug reactions in older adults: an update
10.1007/s40266-023-01064-y · 2023 · External reference
Methods for identifying adverse drug reactions in primary care: a systematic review
10.1371/journal.pone.0317660 · 2025 · External reference
Nurse-led medicines’ monitoring in care homes study protocol: a process evaluation of the impact and sustainability of the adverse drug reaction (ADRe) profile for mental health medicines
10.1136/bmjopen-2018-023377 · 2018 · External reference
Nurse-led medicines’ monitoring for patients with dementia in care homes: a pragmatic cohort stepped wedge cluster randomised trial
10.1371/journal.pone.0140203 · 2015 · External reference
Clinical impact of implementing a nurse-led adverse drug reaction profile in older adults prescribed multiple medicines in UK primary care: a study protocol for a cluster-randomised controlled trial
2022 · External reference
Using nurse-led patient monitoring to avoid medicines-related harm
2021 · External reference
Unresolved reference
External reference
Medication monitoring in a nurse-led respiratory outpatient clinic: pragmatic randomised trial of the West Wales Adverse Drug Reaction Profile
2014 · External reference
Managing adverse drug reactions: an orphan task
10.1046/j.1365-2648.2002.02205.x · 2002 · External reference
Medication monitoring for people with dementia in care homes: the feasibility and clinical impact of nurse-led monitoring
10.1155/2014/843621 · 2014 · External reference
Nurse-led medicines’ monitoring in care homes, implementing the Adverse Drug Reaction (ADRe) Profile improvement initiative for mental health medicines: an observational and interview study
10.1371/journal.pone.0220885 · 2019 · External reference
Nurse-led medicines monitoring: a study examining the effects of the West Wales Adverse Drug Reaction Profile
10.7748/ns.2016.e10447 · 2016 · External reference
Breaking barriers: feasibility of a cluster randomised trial evaluating an instrument for identifying and ameliorating adverse drug reactions
10.1136/bmjopen-2025-099627 · 2026 · External reference
Consort 2010 statement: extension to cluster randomised trials
2012 · External reference
Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide
10.1136/bmj.g1687 · 2014 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
A systematic review of the emerging definition of “deprescribing” with network analysis: implications for future research and clinical practice
10.1111/bcp.12732 · 2015 · External reference
Unresolved reference
External reference
Sample size, power and effect size revisited: simplified and practical approaches in pre-clinical, clinical and laboratory studies
10.11613/bm.2021.010502 · 2021 · External reference
What is an intracluster correlation coefficient? Crucial concepts for primary care researchers
10.1370/afm.141 · 2004 · External reference
Unresolved reference
External reference
LEVEL (Logical Explanations & Visualizations of Estimates in Linear mixed models): recommendations for reporting multilevel data and analyses
10.1186/s12874-019-0876-8 · 2020 · External reference
10.1002/9781119536604
10.1002/9781119536604 · 2019 · External reference
Unresolved reference
2025 · External reference
Unresolved reference
1977 · External reference
Economic impact of adverse drug events – a retrospective population-based cohort study of 4970 adults
10.1371/journal.pone.0092061 · 2014 · External reference
Prevalence and risk factors of drug-related problems identified in pharmacy-based medication reviews
10.1007/s11096-020-00976-8 · 2020 · External reference
Drug-related problems of patients in primary health care institutions: a systematic review
10.3389/fphar.2021.698907 · 2021 · External reference
Clinical trials – Collecting safety data and establishing the ADR Profile.
2012 · External reference
Top 10 signs and symptoms of psychotropic adverse drug events to monitor in residents of long-term care facilities
10.1016/j.jamda.2024.105118 · 2024 · External reference
Effects of a clinical medication review focused on personal goals, quality of life, and health problems in older persons with polypharmacy: a randomised controlled trial (DREAMeR-study)
10.1371/journal.pmed.1002798 · 2019 · External reference
Patient-reported common symptoms as an assessment of interventions in medication reviews: a randomised, controlled trial
10.1007/s11096-017-0575-7 · 2018 · External reference
Pharmacotherapy consultation on polypharmacy patients in ambulatory care
10.1345/aph.10259 · 2001 · External reference
Reducing adverse drug reactions for older people in the community: evaluating the validity and reliability of the ADRe profile
10.1155/jonm/9921349 · 2025 · External reference
Unresolved reference
2017 · External reference
Patients’ clinical information requirements to apply the STOPP/START criteria
10.1007/s11096-019-00920-5 · 2019 · External reference
What are the most common conditions in primary care? Systematic review
2018 · External reference
Recognition of anemia in elderly people in a rural community hospital
10.3390/ijerph182111179 · 2021 · External reference
Educational intervention to improve citizen’s healthcare participation perception in rural japanese communities: a pilot study
10.3390/ijerph18041782 · 2021 · External reference
The contribution of direct patient reported ADRs to drug safety signals in the Netherlands from 2010 to 2015
10.1002/pds.4236 · 2017 · External reference
Insight into the severity of adverse drug reactions as experienced by patients
10.1007/s40264-019-00890-7 · 2020 · External reference
Clinicians’ expectations of the benefits and harms of treatments, screening, and tests: a systematic review
10.1001/jamainternmed.2016.8254 · 2017 · External reference
Unresolved reference
1995 · External reference
The aggregation of marginal gains: a pragmatic philosophy of clinical care in psychiatry
10.1002/wps.21174 · 2024 · External reference
Cost of illness of patient-reported adverse drug events: a population-based cross-sectional survey
10.1136/bmjopen-2013-002574 · 2013 · External reference
Minimizing side-effects: the clinical impact of nurse-administered “side-effect” checklists
10.1046/j.1365-2648.2002.02064.x · 2002 · External reference
Preventable hospital admissions related to medication (HARM): cost analysis of the HARM study
10.1016/j.jval.2010.10.024 · 2011 · External reference
Practical approach to determining costs and frequency of adverse drug events in a health care network
10.1093/ajhp/58.12.1126 · 2001 · External reference
The direct costs of fatal and non-fatal falls among older adults - United States
10.1016/j.jsr.2016.05.001 · 2016 · External reference
Unresolved reference
2020 · External reference
Unresolved reference
External reference
Preventable adverse drug events causing hospitalisation: identifying root causes and developing a surveillance and learning system at an urban community hospital, a cross-sectional observational study
10.1136/bmjoq-2020-001161 · 2021 · External reference
Unresolved reference
External reference
Unresolved reference
2018 · External reference
Unresolved reference
External reference
Unresolved reference
2024 · External reference
Unresolved reference
External reference
Risk prediction models for adverse drug reactions and adverse drug events in older adults-a systematic review and meta-analysis
10.1007/s00228-024-03774-7 · 2025 · External reference
Unresolved reference
External reference
Contamination in trials of educational interventions
2007 · External reference
Avoiding blunders when analyzing correlated data, clustered data, or repeated measures
10.3899/jrheum.2022-1109 · 2023 · External reference
Unresolved reference
1992 · External reference
Unresolved reference
2020 · External reference
Evidence based practice: the debate
10.1111/j.1365-2834.2008.00881.x · 2008 · External reference
Teacher expectations for the disadvantaged
10.1038/scientificamerican0468-19 · 1968 · External reference
Unresolved reference
1939 · External reference
The OEO P.C. experiment and the John Henry Effect
1972 · External reference
Bias in analytic research
10.1016/0021-9681(79)90012-2 · 1979 · External reference
Signals of adverse drug reactions communicated by pharmacovigilance stakeholders: a scoping review of the global literature
10.1007/s40264-022-01258-0 · 2023 · External reference
Inter-rater agreement between WHO- Uppsala monitoring centre system and naranjo algorithm for causality assessment of adverse drug reactions
10.1016/j.vascn.2024.107514 · 2024 · External reference
Agreement between WHO-UMC causality scale and the Naranjo algorithm for causality assessment of adverse drug reactions
10.4103/jfmpc.jfmpc_831_21 · 2021 · External reference
Practical significance: moving beyond statistical significance
10.1016/j.cptl.2015.09.001 · 2016 · External reference
Statistical, practical and clinical significance and Doctor of Nursing Practice projects
10.1111/nae2.27 · 2021 · External reference
Practical significance: a concept whose time has come
10.1177/0013164496056005002 · 1996 · External reference
How effect size (practical significance) misleads clinical practice: the case for switching to practical benefit to assess applied research findings
10.1080/00031305.2018.1549101 · 2019 · External reference
Beyond adoption: a new framework for theorizing and evaluating nonadoption, abandonment, and challenges to the scale-up, spread, and sustainability of health and care technologies
10.2196/jmir.8775 · 2017 · External reference
The NASSS (Non-Adoption, Abandonment, Scale-Up, Spread and Sustainability) framework use over time: a scoping review
2025 · External reference
Looking for the “Little Things”: a multi-disciplinary approach to medicines monitoring for older people using the ADRe resource
10.3390/geriatrics5040079 · 2020 · External reference
Clinicians’ expectations of the benefits and harms of treatments, screening, and tests: a systematic review
10.1001/jamainternmed.2016.8254 · ExternalCitation · doi-reference
Emergency department programs to support medication safety in older adults: a systematic review and meta-analysis
10.1001/jamanetworkopen.2025.0814 · ExternalCitation · doi-reference
10.1002/9781119536604
10.1002/9781119536604 · ExternalCitation · doi-reference
The contribution of direct patient reported ADRs to drug safety signals in the Netherlands from 2010 to 2015
10.1002/pds.4236 · ExternalCitation · doi-reference
The aggregation of marginal gains: a pragmatic philosophy of clinical care in psychiatry
10.1002/wps.21174 · ExternalCitation · doi-reference
Costs associated with adverse drug reactions in an older population admitted to hospital: a prospective cohort study
10.1007/s00228-023-03552-x · ExternalCitation · doi-reference
Risk prediction models for adverse drug reactions and adverse drug events in older adults-a systematic review and meta-analysis
10.1007/s00228-024-03774-7 · ExternalCitation · doi-reference
Patient-reported common symptoms as an assessment of interventions in medication reviews: a randomised, controlled trial
10.1007/s11096-017-0575-7 · ExternalCitation · doi-reference
Patients’ clinical information requirements to apply the STOPP/START criteria
10.1007/s11096-019-00920-5 · ExternalCitation · doi-reference
Prevalence and risk factors of drug-related problems identified in pharmacy-based medication reviews
10.1007/s11096-020-00976-8 · ExternalCitation · doi-reference
Insight into the severity of adverse drug reactions as experienced by patients
10.1007/s40264-019-00890-7 · ExternalCitation · doi-reference
Signals of adverse drug reactions communicated by pharmacovigilance stakeholders: a scoping review of the global literature
10.1007/s40264-022-01258-0 · ExternalCitation · doi-reference
Interventions to reduce adverse drug event-related outcomes in older adults: a systematic review and meta-analysis
10.1007/s40266-019-00738-w · ExternalCitation · doi-reference
Interprofessional interventions involving pharmacists and targeting the medicines management process provided to older people residing in nursing homes: a systematic review and meta-analysis of randomised controlled trials
10.1007/s40266-022-00978-3 · ExternalCitation · doi-reference
Systematic review and meta-analysis of interventions to reduce adverse drug reactions in older adults: an update
10.1007/s40266-023-01064-y · ExternalCitation · doi-reference
Prevalence of and risk factors for drug-related readmissions in older adults: a systematic review and meta-analysis
10.1007/s40266-023-01076-8 · ExternalCitation · doi-reference
Bias in analytic research
10.1016/0021-9681(79)90012-2 · ExternalCitation · doi-reference
Practical significance: moving beyond statistical significance
10.1016/j.cptl.2015.09.001 · ExternalCitation · doi-reference
Top 10 signs and symptoms of psychotropic adverse drug events to monitor in residents of long-term care facilities
10.1016/j.jamda.2024.105118 · ExternalCitation · doi-reference
The direct costs of fatal and non-fatal falls among older adults - United States
10.1016/j.jsr.2016.05.001 · ExternalCitation · doi-reference
Preventable hospital admissions related to medication (HARM): cost analysis of the HARM study
10.1016/j.jval.2010.10.024 · ExternalCitation · doi-reference
Inter-rater agreement between WHO- Uppsala monitoring centre system and naranjo algorithm for causality assessment of adverse drug reactions
10.1016/j.vascn.2024.107514 · ExternalCitation · doi-reference
Incidence and preventability of adverse drug events in nursing homes
10.1016/s0002-9343(00)00451-4 · ExternalCitation · doi-reference
Detection tools for prediction and identification of adverse drug reactions in older patients: a systematic review and meta-analysis
10.1038/s41598-022-17410-w · ExternalCitation · doi-reference
Teacher expectations for the disadvantaged
10.1038/scientificamerican0468-19 · ExternalCitation · doi-reference
Minimizing side-effects: the clinical impact of nurse-administered “side-effect” checklists
10.1046/j.1365-2648.2002.02064.x · ExternalCitation · doi-reference
Managing adverse drug reactions: an orphan task
10.1046/j.1365-2648.2002.02205.x · ExternalCitation · doi-reference
Adverse drug events in ambulatory care
10.1056/nejmsa020703 · ExternalCitation · doi-reference
How effect size (practical significance) misleads clinical practice: the case for switching to practical benefit to assess applied research findings
10.1080/00031305.2018.1549101 · ExternalCitation · doi-reference
Consequences of polypharmacy among the people living with dementia: a systematic review and meta-analysis
10.1080/13607863.2024.2436501 · ExternalCitation · doi-reference
Interventions for reducing anticholinergic medication burden in older adults-a systematic review and meta-analysis
10.1093/ageing/afad176 · ExternalCitation · doi-reference
Practical approach to determining costs and frequency of adverse drug events in a health care network
10.1093/ajhp/58.12.1126 · ExternalCitation · doi-reference
Is polypharmacy always hazardous? A retrospective cohort analysis using linked electronic health records from primary and secondary care
10.1111/bcp.12292 · ExternalCitation · doi-reference
A systematic review of the emerging definition of “deprescribing” with network analysis: implications for future research and clinical practice
10.1111/bcp.12732 · ExternalCitation · doi-reference
Preventable adverse drug events: descriptive epidemiology
10.1111/bcp.14139 · ExternalCitation · doi-reference
The effect of deprescribing interventions on mortality and health outcomes in older people: an updated systematic review and meta-analysis
10.1111/bcp.16200 · ExternalCitation · doi-reference
Trends in adverse drug reaction-related hospitalisations over 13 years in New South Wales, Australia
10.1111/imj.14134 · ExternalCitation · doi-reference
Evidence based practice: the debate
10.1111/j.1365-2834.2008.00881.x · ExternalCitation · doi-reference
Trends in emergency hospital admissions in England due to adverse drug reactions: 2008-2015
10.1111/jphs.12160 · ExternalCitation · doi-reference
Statistical, practical and clinical significance and Doctor of Nursing Practice projects
10.1111/nae2.27 · ExternalCitation · doi-reference
Evaluation of effectiveness and safety of pharmacist independent prescribers in care homes: cluster randomised controlled trial
10.1136/bmj-2022-071883 · ExternalCitation · doi-reference
Adverse events in British hospitals: preliminary retrospective record review
10.1136/bmj.322.7285.517 · ExternalCitation · doi-reference
Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide
10.1136/bmj.g1687 · ExternalCitation · doi-reference
Cost of illness of patient-reported adverse drug events: a population-based cross-sectional survey
10.1136/bmjopen-2013-002574 · ExternalCitation · doi-reference
Interventions to improve the appropriate use of polypharmacy in older people: a Cochrane systematic review
10.1136/bmjopen-2015-009235 · ExternalCitation · doi-reference
Nurse-led medicines’ monitoring in care homes study protocol: a process evaluation of the impact and sustainability of the adverse drug reaction (ADRe) profile for mental health medicines
10.1136/bmjopen-2018-023377 · ExternalCitation · doi-reference
Breaking barriers: feasibility of a cluster randomised trial evaluating an instrument for identifying and ameliorating adverse drug reactions
10.1136/bmjopen-2025-099627 · ExternalCitation · doi-reference
Preventable adverse drug events causing hospitalisation: identifying root causes and developing a surveillance and learning system at an urban community hospital, a cross-sectional observational study
10.1136/bmjoq-2020-001161 · ExternalCitation · doi-reference
Incidence, nature and causes of avoidable significant harm in primary care in England: retrospective case note review
10.1136/bmjqs-2020-011405 · ExternalCitation · doi-reference
Medication monitoring for people with dementia in care homes: the feasibility and clinical impact of nurse-led monitoring
10.1155/2014/843621 · ExternalCitation · doi-reference
Reducing adverse drug reactions for older people in the community: evaluating the validity and reliability of the ADRe profile
10.1155/jonm/9921349 · ExternalCitation · doi-reference
Effect of underlying cardiometabolic diseases on the association between sedentary time and all-cause mortality in a large Japanese population: a cohort analysis based on the J-MICC study
10.1161/jaha.120.018293 · ExternalCitation · doi-reference
Sample size, power and effect size revisited: simplified and practical approaches in pre-clinical, clinical and laboratory studies
10.11613/bm.2021.010502 · ExternalCitation · doi-reference
Practical significance: a concept whose time has come
10.1177/0013164496056005002 · ExternalCitation · doi-reference
An overview of prevalence, determinants and health outcomes of polypharmacy
10.1177/2042098620933741 · ExternalCitation · doi-reference
Ten-year trends in adverse drug reaction-related hospitalizations among people with dementia
10.1177/20420986221080796 · ExternalCitation · doi-reference
LEVEL (Logical Explanations & Visualizations of Estimates in Linear mixed models): recommendations for reporting multilevel data and analyses
10.1186/s12874-019-0876-8 · ExternalCitation · doi-reference
What is polypharmacy? A systematic review of definitions
10.1186/s12877-017-0621-2 · ExternalCitation · doi-reference
The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995-2010
10.1186/s12916-015-0322-7 · ExternalCitation · doi-reference
Analysis of drug-related tinnitus based on the FDA adverse event reporting system database
10.12968/hmed.2024.0380 · ExternalCitation · doi-reference
Pharmacotherapy consultation on polypharmacy patients in ambulatory care
10.1345/aph.10259 · ExternalCitation · doi-reference
What is an intracluster correlation coefficient? Crucial concepts for primary care researchers
10.1370/afm.141 · ExternalCitation · doi-reference
Effects of a clinical medication review focused on personal goals, quality of life, and health problems in older persons with polypharmacy: a randomised controlled trial (DREAMeR-study)
10.1371/journal.pmed.1002798 · ExternalCitation · doi-reference
Economic impact of adverse drug events – a retrospective population-based cohort study of 4970 adults
10.1371/journal.pone.0092061 · ExternalCitation · doi-reference
Nurse-led medicines’ monitoring for patients with dementia in care homes: a pragmatic cohort stepped wedge cluster randomised trial
10.1371/journal.pone.0140203 · ExternalCitation · doi-reference
Nurse-led medicines’ monitoring in care homes, implementing the Adverse Drug Reaction (ADRe) Profile improvement initiative for mental health medicines: an observational and interview study
10.1371/journal.pone.0220885 · ExternalCitation · doi-reference
Nobody ever questions-Polypharmacy in care homes: a mixed methods evaluation of a multidisciplinary medicines optimisation initiative
10.1371/journal.pone.0244519 · ExternalCitation · doi-reference
Prevalence of adverse drug reactions in the primary care setting: a systematic review and meta-analysis
10.1371/journal.pone.0252161 · ExternalCitation · doi-reference
Methods for identifying adverse drug reactions in primary care: a systematic review
10.1371/journal.pone.0317660 · ExternalCitation · doi-reference
The effect of physical multimorbidity, mental health conditions and socioeconomic deprivation on unplanned admissions to hospital: a retrospective cohort study
10.1503/cmaj.121349 · ExternalCitation · doi-reference
Beyond adoption: a new framework for theorizing and evaluating nonadoption, abandonment, and challenges to the scale-up, spread, and sustainability of health and care technologies
10.2196/jmir.8775 · ExternalCitation · doi-reference
Drug-related problems of patients in primary health care institutions: a systematic review
10.3389/fphar.2021.698907 · ExternalCitation · doi-reference
Looking for the “Little Things”: a multi-disciplinary approach to medicines monitoring for older people using the ADRe resource
10.3390/geriatrics5040079 · ExternalCitation · doi-reference
Educational intervention to improve citizen’s healthcare participation perception in rural japanese communities: a pilot study
10.3390/ijerph18041782 · ExternalCitation · doi-reference
Recognition of anemia in elderly people in a rural community hospital
10.3390/ijerph182111179 · ExternalCitation · doi-reference
Avoiding blunders when analyzing correlated data, clustered data, or repeated measures
10.3899/jrheum.2022-1109 · ExternalCitation · doi-reference
Health outcomes and polypharmacy in elderly individuals: an integrated literature review
10.3928/0098-9134-20050901-04 · ExternalCitation · doi-reference
Agreement between WHO-UMC causality scale and the Naranjo algorithm for causality assessment of adverse drug reactions
10.4103/jfmpc.jfmpc_831_21 · ExternalCitation · doi-reference
Nurse-led medicines monitoring: a study examining the effects of the West Wales Adverse Drug Reaction Profile
10.7748/ns.2016.e10447 · ExternalCitation · doi-reference
